0.00Open7.01Pre Close0 Volume0 Open Interest85.00Strike Price0.00Turnover0.00%IV2.80%PremiumDec 27, 2024Expiry Date4.76Intrinsic Value100Multiplier3DDays to Expiry2.25Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma18.03Leverage Ratio--Theta--Rho--Eff Leverage--Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
No comment yet